| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | clopidogrel (Plavix®) |
| Formulation | 75 mg and 300 mg film-coated tablet |
| Reference number | 93 |
| Indication | Prevention of atherothrombotic events in adults with MI (<35d), ischaemic stroke (7d-6m), established peripheral arterial disease, ACS (Non-ST segment elevation [UA or non-Q-wave MI], including those undergoing stent placement post-PCI, in combination with acetylsalicylic acid (ASA); and ST segment elevation, in combination with ASA in medically treated patients eligible for thrombolytic therapy) |
| Company | Sanofi-Aventis Ltd/Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 15/04/2008 |